On April 24, 2014, David A. Reardon, M.D., clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, discussed current immunotherapy treatment options for patients with brain cancer, and how close we are to making these treatments available to more patients.
Dr. Reardon previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years. He completed his residency at John Hopkins Hospital in Maryland, and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors. His work includes using innovative clinical therapeutic agents to improve cure rates in patients with brain and spinal tumors, with particular focus on immunotherapeutics as well as molecular-targeting agents. In 2013, he was elected as the tenth president of the Society for Neuro-Oncology.